USANA Health Sciences (NYSE:USNA) Issues FY 2026 Earnings Guidance

USANA Health Sciences (NYSE:USNA) updated its FY 2026 earnings guidance on Tuesday. The company provided EPS guidance of 1.950-2.29 for the period, compared to the consensus EPS estimate of 1.800. The company issued revenue guidance of $925.0 million-$1.0 billion, compared to the consensus revenue estimate of $943.7 million.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on USNA. Zacks Research raised shares of USANA Health Sciences from a “strong sell” rating to a “hold” rating in a research report on Monday, February 16th. Wall Street Zen raised shares of USANA Health Sciences from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of USANA Health Sciences in a report on Monday, December 29th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, USANA Health Sciences currently has a consensus rating of “Reduce”.

USANA Health Sciences Stock Performance

USNA stock opened at $19.29 on Thursday. USANA Health Sciences has a fifty-two week low of $18.48 and a fifty-two week high of $38.32. The company has a market capitalization of $352.62 million, a price-to-earnings ratio of 35.07, a price-to-earnings-growth ratio of 0.81 and a beta of 0.64. The business’s 50 day moving average price is $20.82 and its two-hundred day moving average price is $22.98.

USANA Health Sciences (NYSE:USNA) last released its earnings results on Tuesday, February 17th. The company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.19. USANA Health Sciences had a return on equity of 6.75% and a net margin of 1.16%.The company had revenue of $226.20 million during the quarter, compared to analysts’ expectations of $225.96 million. Sell-side analysts forecast that USANA Health Sciences will post 2.45 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Joshua Foukas sold 4,461 shares of the business’s stock in a transaction on Friday, February 20th. The shares were sold at an average price of $21.34, for a total transaction of $95,197.74. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.63% of the company’s stock.

Institutional Investors Weigh In On USANA Health Sciences

Hedge funds have recently bought and sold shares of the business. AQR Capital Management LLC grew its holdings in USANA Health Sciences by 82.8% in the first quarter. AQR Capital Management LLC now owns 21,845 shares of the company’s stock worth $589,000 after purchasing an additional 9,894 shares during the period. Empowered Funds LLC bought a new stake in shares of USANA Health Sciences in the 1st quarter worth approximately $687,000. Russell Investments Group Ltd. boosted its position in shares of USANA Health Sciences by 31.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 13,377 shares of the company’s stock worth $408,000 after purchasing an additional 3,198 shares in the last quarter. Quantbot Technologies LP grew its stake in shares of USANA Health Sciences by 19.5% in the 2nd quarter. Quantbot Technologies LP now owns 3,957 shares of the company’s stock worth $121,000 after buying an additional 646 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in shares of USANA Health Sciences in the 2nd quarter worth approximately $422,000. Institutional investors own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.